Last updated on September 2017

A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia


Brief description of study

The study will examine the safety profile of SGN-CD123A. The study will test increasing doses of SGN-CD123A given every 3 weeks to patients.

Detailed Study Description

This study is designed to evaluate the safety, tolerability, and preliminary estimate of antitumor activity of SGN-CD123A. The study will be conducted in 2 parts: 1. Part A is the dose-escalation portion of the trial, designed to identify the maximum tolerated dose (MTD) of SGN-CD123A 2. Part B is the dose-expansion portion of the trial, designed to evaluate SGN-CD123A in patients with differing CD123 expression levels Dose-escalation in Part A will be conducted using a 3+3 study design. Patients with CD123-detectable AML will be enrolled in cohorts at escalating doses of study drug and will receive up to 2 induction cycles of SGN-CD123A treatment at an assigned dose level in 3-week cycles. After completion of dose-escalation, patients will be enrolled in Part B of the study. Patients enrolled in Part B will receive up to 2 induction cycles of SGN-CD123A treatment at a dose level and frequency determined by results in Part A. For both Part A and Part B, a third induction cycle may be permitted with the approval of the study medical monitor. If a patient achieves a complete remission or complete remission with incomplete hematologic recovery, optional post-remission cycles of SGN-CD123A may be administered.

Clinical Study Identifier: NCT02848248

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Harry Erba

University of Alabama at Birmingham
Birmingham, AL United States
  Connect »

Guido Marcucci

City of Hope National Medical Center
Duarte, CA United States
  Connect »

Daniel Pollyea

University of Colorado Hospital / University of Colorado
Aurora, CO United States
  Connect »

Amir Fathi

Massachusetts General Hospital
Boston, MA United States
  Connect »

Karen Seiter

Hudson Valley Hematology and Oncology Associates/New York Medical College
Hawthorne, NY United States
  Connect »

Farhad Ravandi-Kashani

MD Anderson Cancer Center / University of Texas
Houston, TX United States
  Connect »

Roland Walter

Fred Hutchinson Cancer Research Center
Seattle, WA United States
  Connect »